$274 Million

Revolution Medicines

Initial Public Offering

Bookrunner, February 2020

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with emphasis on the RAS and mTOR signaling pathways.

More Like This

Jul 2020
$144 Million

Initial Public Offering

Sole Bookrunner

View Details
Jun 2020
$244 Million

Initial Public Offering

Bookrunner

View Details
Jun 2020
$213 Million

Initial Public Offering

Bookrunner

View Details